Elevated Plasma Pentraxin 3 and Its Association with Retinal Vein Occlusion
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate plasma pentraxin 3 (PTX3) in patients with retinal vein occlusion (RVO), and investigatethe possibility of its role as a predictive biomarker. Methods: Nested case-control study. The study included 57 patients with RVO and 45 age- and gender-matched subjects without RVO as controls. Plasma PTX3 and C-reactive protein concentration weremeasured in both groups a posteriori from frozen samples by using an enzyme-linked immunosorbent assaykit. Results: The measured PTX3 value for the RVO group was 1,508 ± 1,183 pg/mL (mean ± standard deviation)and 833 ± 422 pg/mL for the controls (p < 0.001). There was no significant difference in PTX3 levels betweenpatients with central retinal vein occlusion and branched retinal vein occlusion (1,468 ± 1,300 vs. 1,533 ± 1,121pg/mL; p = 0.818). Conclusions: Our data seems to support the role of chronic inflammation and ischemia in the development ofRVO. It is possible that PTX3 can be used as a diagnostic biomarker of RVO.
Abstract
Purpose: To evaluate plasma pentraxin 3 (PTX3) in patients with retinal vein occlusion (RVO), and investigatethe possibility of its role as a predictive biomarker. Methods: Nested case-control study. The study included 57 patients with RVO and 45 age- and gender-matched subjects without RVO as controls. Plasma PTX3 and C-reactive protein concentration weremeasured in both groups a posteriori from frozen samples by using an enzyme-linked immunosorbent assaykit. Results: The measured PTX3 value for the RVO group was 1,508 ± 1,183 pg/mL (mean ± standard deviation)and 833 ± 422 pg/mL for the controls (p < 0.001). There was no significant difference in PTX3 levels betweenpatients with central retinal vein occlusion and branched retinal vein occlusion (1,468 ± 1,300 vs. 1,533 ± 1,121pg/mL; p = 0.818). Conclusions: Our data seems to support the role of chronic inflammation and ischemia in the development ofRVO. It is possible that PTX3 can be used as a diagnostic biomarker of RVO.
참고문헌 (30)
- Shahid H, "The management of retinal vein occlusion: is interventional ophthalmology the way forward?", Br J Ophthalmol, 90, pp.627~639 (2006)
- Funk M, "Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab", Invest Ophthalmol Vis Sci, 50, pp.1025~1032 (2009)
- Jo N, "Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury", Invest Ophthalmol Vis Sci, 44, pp.4054~4060 (2003)
- Pe’er J, "Vascular endothelial growth factor upregulation in human central retinal vein occlusion", Ophthalmology, 105, pp.412~416 (1998)
- Lee HB, "Role of inflammation in retinal vein occlusion", Can J Ophthalmol, 42, pp.131~133 (2007)
- Rifai N, "High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease", Clin Chem, 47, pp.403~411 (2001)
- Ridker PM, "Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease", Circulation, 97, pp.425~428 (1998)
- Goodman AR, "Long pentraxins:an emerging group of proteins with diverse functions", Cytokine Growth Factor Rev, 7, pp.191~202 (1996)
- Manfredi AA, "Pentraxins, humoral innate immunity and tissue injury", Curr Opin Immunol, 20, pp.538~544 (2008)
- Pepys MB, "C-reactive protein: a critical update", J Clin Invest, 111, pp.1805~1812 (2003)
- Noma H, "Pentraxin 3and other inflammatory factors in central retinal vein occlusion and macular edema", Retina, 34, pp.352~359 (2014)
- Bottazzi B, "Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component", J Biol Chem, 272, pp.32817~32823 (1997)
- Garlanda C, "Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility", Annu Rev Immunol, 23, pp.337~366 (2005)
- Tousoulis D, "Pro-inflammatory cytokines in acute coronary syndromes:from bench to bedside", Cytokine Growth Factor Rev, 17, pp.225~233 (2006)
- Alberti L, "Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors", Atherosclerosis, 202, pp.455~460 (2009)
- Woo JM, "Human retinal pigment epithelial cells express the long pentraxin PTX3", Mol Vis, 19, pp.303~310 (2013)
- Hansson GK, "Immune mechanisms in atherosclerosis", Arterioscler Thromb Vasc Biol, 21, pp.1876~1890 (2001)
- Deban L, "Regulation of leukocyte recruitment by the long pentraxin PTX3", Nat Immunol, 11, pp.328~334 (2010)
- Souza DG, "The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice", Am J Pathol, 174, pp.1309~1318 (2009)
- Foteinos G, "Immune-mediated mechanisms of endothelial damage in atherosclerosis", Autoimmunity, 42, pp.627~633 (2009)
- Rolph MS, "Production of the long pentraxin PTX3 in advanced atherosclerotic plaques", Arterioscler Thromb Vasc Biol, 22, pp.e10~e14 (2002)
- Yu HI, "C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus", Diabet Med, 21, pp.336~341 (2004)
- Kume N, "Pentraxin 3as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage", J Cardiol, 58, pp.38~45 (2011)
- 이동현, "Pentraxin 3 as a Novel Marker Predicting Congestive Heart Failure in Subjects With Acute Coronary Syndrome", Korean Circulation Journal, 40(8), pp.370~376 (2010), 대한심장학회
- Jenny NS, "Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study", Arterioscler Thromb Vasc Biol, 29, pp.594~599 (2009)
- Peri G, "PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans", Circulation, 102, pp.636~641 (2000)
- Akerfeldt T, "Pentraxin 3 increase is much less pronounced than C-reactive protein increase after surgical procedures", Inflammation, 34, pp.367~370 (2011)
- Martin SC, "Cardiovascular risk assessment in patients with retinal vein occlusion", Br J Ophthalmol, 86, pp.774~776 (2002)
- Mitchell P, "Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study", Arch Ophthalmol, 114, pp.1243~1247 (1996)
- Nissen SE, "Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease", N Engl J Med, 352, pp.29~38 (2005)